# GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies

> **NCT05880043** · PHASE1,PHASE2 · RECRUITING · sponsor: **GI Cell, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Relapsed/Refractory Non-Hodgkin Lymphoma
- Relapsed/Refractory Multiple Myeloma

## Interventions

- **DRUG:** GIC-102
- **DRUG:** GIC-102

## Key facts

- **NCT ID:** NCT05880043
- **Lead sponsor:** GI Cell, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-28
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05880043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05880043, "GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05880043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*